Assessment of Patient Experiences with Respimat® in Everyday Clinical Practice

• DOI: 10.1007/s41030-020-00127-4
• Publication Date: 2020-08-28T14:03:15Z
• Authors: Christian Taube; Valentina Bayer; Christoph Michael...; Arschang Valipour
• Keywords: Lama; Obstructive lung disease; Bronchodilation

Chronic obstructive pulmonary disease (COPD) is a progressive requiring maintenance therapy. According to the Global Initiative for Obstructive Lung Disease (GOLD) strategy report, bronchodilation with long-acting muscarinic antagonists (LAMAs) and β2-agonists (LABAs), administered via inhalers, currently mainstay of COPD treatment. Combined LAMA/LABA therapies have been shown improve patient health status, lung function breathlessness. Here, we wanted report satisfaction Respimat® Soft Mist™ inhaler (SMI). This was pooled analysis SPIRIT® (NCT02675517) OTIVACTO® (NCT02719639), two open-label, single-arm, non-interventional studies physical in patients COPD. Patients were treated tiotropium/olodaterol 5/5 μg approximately 6 weeks SMI. SPIRIT conducted Germany; OTIVACTO nine European countries. The primary endpoints reported previously. assess inhalation handling, adherence treatment SMI These assessed through self-reported questionnaires physician general assessments. Baseline data collected from 9180 studies. majority GOLD group A (25.59%) or B (46.12%). After tiotropium/olodaterol, 85.78% 'satisfied' 'very satisfied' inhaling device, 84.33% handling inhaler. Treating physicians as 'high' during study, 98.57% regularly using Furthermore, 95.45% expressed willingness continue at end observation period. In this over 9000 respect Respimat SMI, high. ClinicalTrials.gov: NCT02675517 (SPIRIT) NCT02719639 (OTIVACTO). Inhalation devices are main method delivering treatments chronic (COPD). However, there many available, which can lead confusion poor technique. To help doctors decide device give their patients, they consider whether would be happy use it correctly. study large real-life included on range baseline therapies. trial 85% satisfied very 84% device. Physicians that nearly 99% used Also, 95% population continued study. Overall, these results support view across wide severities characteristics demonstrated control disease.